vs
Side-by-side financial comparison of AIM ImmunoTech Inc. (AIM) and Revolution Medicines, Inc. (RVMD). Click either name above to swap in a different company.
Over the past eight quarters, AIM ImmunoTech Inc.'s revenue compounded faster (-27.5% CAGR vs -100.0%).
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
AIM vs RVMD — Head-to-Head
Income Statement — Q4 2025 vs Q4 2024
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $0 |
| Net Profit | $-4.2M | $-194.6M |
| Gross Margin | — | — |
| Operating Margin | -14057.1% | — |
| Net Margin | -19881.0% | — |
| Revenue YoY | -53.3% | — |
| Net Profit YoY | 30.0% | -20.4% |
| EPS (diluted) | $-6.46 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | — | ||
| Q3 25 | $26.0K | — | ||
| Q2 25 | $25.0K | — | ||
| Q1 25 | $16.0K | — | ||
| Q4 24 | $45.0K | $0 | ||
| Q3 24 | $35.0K | $0 | ||
| Q2 24 | $50.0K | $0 | ||
| Q1 24 | $40.0K | $0 |
| Q4 25 | $-4.2M | — | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.8M | — | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | $-6.0M | $-194.6M | ||
| Q3 24 | $-3.7M | $-156.3M | ||
| Q2 24 | $-1.8M | $-133.2M | ||
| Q1 24 | $-5.8M | $-116.0M |
| Q4 25 | -14057.1% | — | ||
| Q3 25 | -9411.5% | — | ||
| Q2 25 | -10584.0% | — | ||
| Q1 25 | -22618.8% | — | ||
| Q4 24 | -13011.1% | — | ||
| Q3 24 | -12825.7% | — | ||
| Q2 24 | -7388.0% | — | ||
| Q1 24 | -14335.0% | — |
| Q4 25 | -19881.0% | — | ||
| Q3 25 | -12630.8% | — | ||
| Q2 25 | -11176.0% | — | ||
| Q1 25 | -23156.3% | — | ||
| Q4 24 | -13260.0% | — | ||
| Q3 24 | -10571.4% | — | ||
| Q2 24 | -3672.0% | — | ||
| Q1 24 | -14542.5% | — |
| Q4 25 | $-6.46 | — | ||
| Q3 25 | $1.57 | — | ||
| Q2 25 | $-3.68 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-21.80 | $-1.13 | ||
| Q3 24 | $-6.00 | $-0.94 | ||
| Q2 24 | $-3.00 | $-0.81 | ||
| Q1 24 | $-0.12 | $-0.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $2.3B |
| Total DebtLower is stronger | $4.5M | — |
| Stockholders' EquityBook value | $-9.8M | $2.3B |
| Total Assets | $5.8M | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $835.0K | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $4.0M | $2.3B | ||
| Q3 24 | $7.2M | $1.5B | ||
| Q2 24 | $10.1M | $1.6B | ||
| Q1 24 | $10.9M | $1.7B |
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $-9.8M | — | ||
| Q3 25 | $-6.1M | — | ||
| Q2 25 | $-6.5M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-1.3M | $2.3B | ||
| Q3 24 | $2.9M | $1.6B | ||
| Q2 24 | $6.1M | $1.6B | ||
| Q1 24 | $4.8M | $1.7B |
| Q4 25 | $5.8M | — | ||
| Q3 25 | $5.5M | — | ||
| Q2 25 | $4.1M | — | ||
| Q1 25 | $6.2M | — | ||
| Q4 24 | $8.6M | $2.6B | ||
| Q3 24 | $13.6M | $1.8B | ||
| Q2 24 | $15.7M | $1.8B | ||
| Q1 24 | $16.2M | $1.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $-138.3M |
| Free Cash FlowOCF − Capex | — | $-139.5M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-567.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $-5.1M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-4.0M | $-138.3M | ||
| Q3 24 | $-3.1M | $-130.4M | ||
| Q2 24 | $-3.0M | $-128.2M | ||
| Q1 24 | $-4.8M | $-160.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | — | $-130.6M | ||
| Q1 24 | — | $-163.7M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
